Published online Jul 27, 2023. doi: 10.4254/wjh.v15.i7.904
Peer-review started: March 27, 2023
First decision: April 19, 2023
Revised: May 17, 2023
Accepted: June 12, 2023
Article in press: June 12, 2023
Published online: July 27, 2023
Processing time: 116 Days and 1 Hours
Intrahepatic cholestasis of pregnancy (ICP) is a rare but severe hepatic complication for both mother and unborn child. Diagnosis is normally based on elevated serum levels of bile acids. Unfortunately, these blood tests usually take several hours, even at maximum care facilities. So far, there are no screening test for liver disease in pregnancy besides serological testing for viral hepatitis in the third trimester.
Measurement of liver stiffness (LS) through elastographic techniques has become the novel gold standard for the non-invasive diagnosis of liver cirrhosis often avoiding invasive liver biopsies. LS is not only highly correlated to the hepatic fibrosis stage but can also be elevated due to other important confounding factors such as inflammation, congestion or cholestasis. For these reasons, liver elastography could be an ideal diagnostic tool to address hepatic complications during pregnancy.
The aim of the present study was to specifically explore LS in a large cohort of women with ICP before and after delivery compared to a control group with uncomplicated pregnancy.
LS and the hepatic steatosis marker controlled attenuation parameter (CAP) were measured in 100 pregnant women with ICP using transient elastography (Fibroscan, Echosens, Paris, France). In 17 cases, LS could be measured after delivery. A large cohort of women with uncomplicated pregnancy served as control group. Routine laboratory, levels of bile acids and the apoptosis marker M30 were also measured.
In the third trimester, women with ICP show a significantly increased LS at 7.3 ± 3.0 kPa compared to controls (6.2 ± 2.3 kPa, P < 0.0001). LS decreases significantly 24 h after deliver and remains higher in ICP (5.8 ± 1.7 kPa vs 4.2 ± 0.9 kPa, P < 0.0001). In ICP, LS is mainly correlated with levels of bile acids and the apoptosis marker M30. No correlation was seen with GGT and GGT even increased after delivery in women with ICP.
In conclusion, LS is significantly elevated in ICP which is most likely due to toxic bile acid accumulation and hepatocyte apoptosis. In association with conventional laboratory markers, LS provides additional non-invasive information to rapidly identify women at risk for ICP.
In the future, elastography should be further validated in order to early identify women at risk for complications. Moreover, elastography studies should be combined with genetic risk assessment, as several mutations of bile transport proteins are involved in the development of ICP.